RT Journal Article
ID 5765c0573ab7f056
A1 Masoud, Muhammad Shareef
A1 Ashfaq, Usman Ali
A1 Khalid, Hina 
T1 Interferon-Free Regimen for Hepatitis C: Insight and Management
JF Critical Reviews™ in Eukaryotic Gene Expression
JO CRE
YR 2018
FD 2018-09-11
VO 28
IS 4
SP 373
OP 384
K1 NS3 protease inhibitor
K1 NS5B inhibitor
K1 HCV
AB The rapid development of direct-acting antiviral agents (DAA) for hepatitis C virus (HCV) therapy dramatically altered the treatment landscape of this disease. The DAA regimen is associated with various advantages including high sustained virological response (SVR) with minimum side effects and low pill load and specific inhibition of viral replication, which lowers dependence on the host cell. This regimen has substantially replaced conventional (interferon) therapy with high cure rates (> 90%) in most HCV populations. This review provides insight into clinical studies of NS3/4A protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors, alone and in combination.
PB Begell House
LK https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,0a9875bd7f54033e,5765c0573ab7f056.html